Fernando C. Fervenza
Consultant, Division of Nephrology & Hypertension, Department of Internal Medicine · Mayo Clinic
Credentials: · · ·
History
- Present
Hospital Sao Lucas of the Pontificia Universidade Catolica do Rio Grande do Sul
Hospital Sao Lucas of the Pontificia Universidade Catolica do Rio Grande do Sul
Medical School of the Pontificia Universidade Catolica do Rio Grande do Sul
Research
Rituximab versus cyclophosphamide for ANCA-associated vasculitis
New England Journal of Medicine · 2010 · 2,067 citations
Arthritis & Rheumatism · 2012 · 1,098 citations
Kidney International · 2009 · 1,025 citations
177 papers
76 papers · 10 as a resident
69 papers
67 papers
58 papers
- LC
28 papers
27 papers · 8 as a resident
26 papers
Grants
- 2009–2014
Nephrotic Syndrome Rare Disease Clinical Research Network III
National Institute of Diabetes and Digestive and Kidney Diseases · U54
Project lead · $4.5M · University of Michigan at Ann Arbor
- 2003–2005
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $4K · Mayo Clinic Rochester
Clinical trials
- 2025–2029
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Principal investigator · Recruiting · Phase 2
Mayo Clinic
- 2024–2026
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Principal investigator · Recruiting · Phase 2
Mayo Clinic
- 2023–2028
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
Principal investigator · Active not recruiting · Phase 2
Mayo Clinic
- 2021–2025